See every side of every news story
Get Started
SubscribeLogin
Hamas
Donald Trump
Ukraine War
Israel-Hamas Conflict
Volodymyr Zelenskyy
Elon Musk
Basketball
Artificial Intelligence
Climate Change
Premier League
Vladimir Putin
US Politics
Published • loading... • Updated

Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker

Summary by CNBC
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

7 Articles

All
Left
Center
1
Right
CNBCCNBC
Reposted by
Stockxpo - A professional network of traders, investors and analystsStockxpo - A professional network of traders, investors and analysts

Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

·United States
Read Full Article
MedCity NewsMedCity News

Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity

Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million. Meanwhile, Pfizer continued the culling of its gene therapies with the discontinuation of Beqvez for hemophilia B. The post Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity appeared first on MedCity News.

Read Full Article
citybizcitybiz

bluebird bio to be Acquired by Carlyle and SK Capital

SOMERVILLE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (NASDAQ: BLUE) today announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP in collaboration with a team of highly experienced biotech executives. David Meek, former CEO of Mirati Therapeutics and Ipsen, is expected to become CEO of bluebird upon closing. Carlyle and SK Capital will p…

Read Full Article
pharmaceutical-technology.compharmaceutical-technology.com

Struggling bluebird bio to go private for less than $30m - Pharmaceutical Technology

Bluebird has faced financial pressures over the last few years, leading to several restructuring efforts.

Read Full Article
Endpoints NewsEndpoints News

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

A pair of investors will acquire bluebird bio in a deal worth only $29 million upfront after the gene therapy maker ran out of time and options. The company has struggled financially even as it ...

Read Full Article
csimarket.comcsimarket.com

#Bluebird Bio Enters New Chapter Strategic Acquisition by Carlyle and SK Capital to Drive Growth Amidst Market Struggles

Bluebird Bio, Inc. (NASDAQ: BLUE), a biotechnology company known for its innovative approaches to gene therapy, recently announced a definitive agreement to be acquired by global investment firms Carlyle and SK Capital Partners, LP. This strategic move comes amid a challenging period for Bluebird, as its shares have been trailing the broader market and failing to keep pace with its competitors in the biotech space. The definitive acquisition agr…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

csimarket.com broke the news in on Friday, February 21, 2025.
Sources are mostly out of (0)

Similar News Topics

News
For You
Search
BlindspotLocal